Is mizoribine a new therapeutic agent for Sjogren's syndrome?

Moutsopoulos, HM; Fragoulis, GE

dc.contributor.author	Moutsopoulos, HM	en
dc.contributor.author	Fragoulis, GE	en
dc.date.accessioned	2014-03-01T11:46:21Z
dc.date.available	2014-03-01T11:46:21Z
dc.date.issued	2008	en
dc.identifier.issn	1745-8382	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/37828
dc.subject	immunosuppression	en
dc.subject	mizoribine	en
dc.subject	sicca symptoms	en
dc.subject	sjogren's syndrome	en
dc.subject	therapy	en
dc.subject.classification	Rheumatology	en
dc.subject.classification	Social Issues	en
dc.title	Is mizoribine a new therapeutic agent for Sjogren's syndrome?	en
heal.type	other	en
heal.language	English	en
heal.publicationDate	2008	en
heal.abstract	In a multicenter, open-label study conducted in Japan between July 2004 and May 2005, Nakayamada et al. tested the safety and efficacy of mizoribine for the treatment of primary Sjogren's syndrome (pSS). Mizoribine 50 mg was administered three times a day for 16 weeks to 59 patients with pSS, 7 of whom withdrew because of adverse drug reactions; however, no serious adverse events were noted. In the 48 patients who completed the study, an increase from baseline in median salivary secretion volume, evaluated using the Saxon test, was apparent at week 8 and was significant at week 16 (P <0.05). At 16 weeks, significant improvements from baseline were also seen in patients' assessments of dry mouth and dry eyes, physicians' assessment of oral sicca symptoms, labioangular sicca symptoms and physicians' overall assessment, all measured using a 10 cm visual analog scale. The findings suggest that mizoribine could be an effective treatment for pSS.	en
heal.publisher	NATURE PUBLISHING GROUP	en
heal.journalName	NATURE CLINICAL PRACTICE RHEUMATOLOGY	en
dc.identifier.isi	ISI:000257268800008	en
dc.identifier.volume	4	en
dc.identifier.issue	7	en
dc.identifier.spage	350	en
dc.identifier.epage	351	en